# Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension

> **NCT02558374** · PHASE3 · COMPLETED · sponsor: **Aerie Pharmaceuticals** · enrollment: 708 (actual)

## Conditions studied

- Open-angle Glaucoma
- Ocular Hypertension

## Interventions

- **DRUG:** AR-13324 Ophthalmic Solution 0.02%
- **DRUG:** Timolol Maleate Ophthalmic Solution 0.5% BID
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02558374
- **Lead sponsor:** Aerie Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 708 (ACTUAL)
- **Last updated:** 2018-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02558374

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02558374, "Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02558374. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*